Boryung succeeded in crossing the first hurdle in the patent challenge for Lenvima, a liver cancer treatment. If the remaining two patents are avoided or invalidated, the early generic release is expected to be faster. According to the pharmaceutical industry on the 23rd, the Intellectual Property Trial and Appeals Board sided with Boryeong in a recent trial to confirm the scope of rights for a crystalline form of Lenvima, which Boryeong recently filed against Eisai.

Boryeong is single-handedly challenging Lenvima patents. In November of last year, it filed a simultaneous request for a negative right scope confirmation trial and an invalidation trial for three Lenvima patents. At the time, Daewoong Phar